The Impact of Intestinal Microorganisms and Their Metabolites on Type 1 Diabetes Mellitus
Shu-Juan Zheng,Yi Luo,Jian-Hui Xiao
DOI: https://doi.org/10.2147/DMSO.S355749
2022-04-12
Abstract:Shu-Juan Zheng, 1 Yi Luo, 1, 2 Jian-Hui Xiao 1, 2 1 Zunyi Municipal Key Laboratory of Medicinal Biotechnology, Affiliated Hospital of Zunyi Medical University, Zunyi, 563003, People's Republic of China; 2 Guizhou Provincial Research Center for Translational Medicine, Affiliated Hospital of Zunyi Medical University, Zunyi, 563003, People's Republic of China Correspondence: Jian-Hui Xiao, Guizhou Provincial Research Center for Translational Medicine, Affiliated Hospital of Zunyi Medical University, 149 Dalian Road, HuiChuan District, Zunyi, 563003, People's Republic of China, Email Background: Type 1 diabetes mellitus (T1DM) is an autoimmune disease with a complex etiology comprising numerous genetic and environmental factors; however, many of the mechanisms underlying disease development remain unclear. Nevertheless, a critical role has recently been assigned to intestinal microorganisms in T1DM disease pathogenesis. In particular, a decrease in intestinal microbial diversity, increase in intestinal permeability, and the translocation of intestinal bacteria to the pancreas have been reported in patients and animal models with T1DM. Moreover, intestinal microbial metabolites differ between healthy individuals and patients with T1DM. Specifically, short-chain fatty acid (SCFA) production, which contributes to intestinal barrier integrity and immune response regulation, is significantly reduced in patients with T1DM. Considering this correlation between intestinal microorganisms and T1DM, many studies have investigated the potential of intestinal microbiota in preventive and therapeutic strategies for T1DM. Objective: The aim of this review is to provide further support for the notion that intestinal microbiota contributes to the regulation of T1DM occurrence and development. In particular, this article reviews the involvement of the intestinal microbiota and the associated metabolites in T1DM pathogenesis, as well as recent studies on the involvement of the intestinal microbiota in T1DM prevention and treatment. Conclusion: Intestinal microbes and their metabolites contribute to T1DM occurrence and development and may become a potential target for novel therapeutics. Keywords: type 1 diabetes mellitus, intestinal microorganisms, intestinal microbiota, dysbiosis, metabolites, prevention and treatment Type 1 diabetes mellitus (T1DM) is an autoimmune disease caused by islet atopic T cells that damage islet β cells, resulting in insufficient insulin secretion. According to recent estimates by the International Diabetes Federation, as of 2019, 463 million people, including 1.1 million children and adolescents under the age of 20 years, worldwide have been diagnosed with diabetes. Meanwhile, T1DM often has acute (diabetic ketoacidosis) or short-term (diabetic eye, kidney, and other diseases) complications caused by extreme blood sugar levels, which can lead to permanent disease and even death. Environmental factors synergize with genetic susceptibility to promote TIDM development. In particular, environmental factors, including intestinal microorganisms, have central roles in T1DM pathogenesis. 1 Typically, in healthy individuals, intestinal microorganisms are in a state of dynamic equilibrium; however, when this balance is disrupted, various chronic diseases can develop. In the context of T1DM, unique microbiome structures with poor stability and low diversity have been defined for patients with T1DM compared to healthy individuals. 2,3 Meanwhile, patients with T1DM who have undergone treatment develop microbiota that resembles that of healthy individuals, thus supporting a role for the intestinal microbiota in T1DM development and/or pathogenesis. Accordingly, it has been postulated that intestinal microbiota may serve as a target for the prevention and treatment of T1DM. That is, restricting the growth of disease-associated microorganisms, or enhancing, within an effective range, the growth of microorganisms that favorably impact disease outcome, may prove to be successful strategies for treating or preventing T1DM. Current methods for disease prevention or treatment that influence gut microbiota include dietary fiber supplementation, probiotic intake, and breastfeeding, further proving that the intestinal microbiota is involved in the regulation of the disease. The primary aim of the current article is to further investigate and collate the current literature related to the regulatory role of the intestinal microbiome in T1DM occurrence and development, while also providing new insights into the involvement of intestinal microbiota, and their metabolites, in T1DM pathogenesis. The intestinal tract, which contains a myriad of microbes, is the largest immune o -Abstract Truncated-